<DOC>
	<DOC>NCT00686036</DOC>
	<brief_summary>The purpose of this study is to determine whether treatment with Zactima for up to 18 months will prolong the off-treatment interval in patients who are undergoing intermittent androgen deprivation therapy.</brief_summary>
	<brief_title>Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Diagnosis of prostate cancer Prostate specific antigen (PSA) greater than or equal to 5 ng/mL Recent completion of first hormone treatment [intermittent androgen deprivation with a Luteinising hormone releasing hormone (LHRH) analogue] Screening PSA â‰¤1.0 ng/mL (within 6 weeks prior to study Day1) Bone or soft tissue metastases Significant cardiovascular disease including hypertension not controlled by medical therapy or history of irregular heart beats or recent heart attack</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>hormone treatment</keyword>
</DOC>